A simple, precise, accurate and rapid high-performance thin-layer chromatographic method has been developed and validated for the estimation of atorvastatin calcium and ezetimibe simultaneously in combined dosage forms. The stationary phase used was precoated silica gel 60F 254 . The mobile phase used was a mixture of chloroform: benzene: methanol: acetic acid (6.0:3.0:1.0:0.1 v/v/v/v). The detection of spots was carried out at 250 nm. The method was validated in terms of linearity, accuracy, precision and specificity. The calibration curve was found to be linear between 0.8 and 4.0 µg/spot for atorvastatin calcium and 0.1 and 1.0 µg/spot for ezetimibe. The limit of detection and the limit of quantification for atorvastatin calcium were found to be 170 ng/spot and 570 ng/spot respectively, and for ezetimibe, 20 ng/spot and 70 ng/spot respectively. The proposed method can be successfully used to determine the drug content of marketed formulation.
The combination of atorvastatin calcium and ezetimibe determination of atorvastatin calcium and ezetimibe in has recently been introduced in the market. Atorvastatin pharmaceutical dosage forms. The objective of the calcium 1,2 is a synthetic lipid lowering agent which inhibits present work was to develop an accurate, specific and HMG CoA reductase, and ezetimibe 3,4 inhibits the reproducible method for the simultaneous estimation of absorption of cholesterol, decreasing the delivery of atorvastatin calcium and ezetimibe in pharmaceutical intestinal cholesterol to the liver. Chemically, atorvastatin calcium is [R-(R*,R*)-2-(4-flurophenyl)-β-dihydroxy-5-(1 methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H pyrrole-1-heptonic acid-calcium salt (2:1) trihydrate [5] [6] [7] , and ezetimibe is (3R,4S)-1-(4-flurophenyl)-3-[(3S)-3-(4 flurophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2 azetidinone 5, [8] [9] . Atorvastatin calcium and ezetimibe are not official in IP, BP or USP. HPLC method has been reported for the determination of atorvastatin and its impurities in bulk drug and tablets 10 . No analytical method has so far been reported for the simultaneous *For correspondence E-mail: nmp_pharmacist@rediffmail.com dosage forms.
Atorvastatin calcium and ezetimibe working standards were procured as gift samples from Torrent Research Centre, Ahmedabad. Silica gel 60F 254 TLC plates (E. Merck, Mumbai) were used as a stationary phase. Tablets containing 10 mg each of atorvastatin calcium and ezetimibe were purchased from the local market (Zetistat-10, Torrent Pharmaceuticals Ltd.). A Camag HPTLC system comprising of Camag Linnomate V automatic sample applicator, Hamilton syringe, Camag TLC Scanner 3, Camag WinCATS software, Camag twin-trough chamber and ultrasonicator was used during the study. Working standards of atorvastatin calcium and ezetimibe (10 mg each) were weighed accurately and diluted with methanol to obtain a final concentration of 1 mg/ml for atorvastatin calcium and 100 µg/ml for ezetimibe. The contents of 20 tablets were ground to a fine powder. Weight equivalent to 25 mg each of atorvastatin calcium and ezetimibe was transferred to a conical flask and dissolved in methanol. The solution was sonicated for 15 min. The extract was filtered through Whatman filter paper No. 41, and the residue was washed with methanol. The extract and washing were pooled and transferred to method was validated [11] [12] [13] by establishing linearity, accuracy, inter-day and intra-day precision, specificity, repeatability of measurement of peak, as well as repeatability of sample application. The limit of detection and limit of quantification were also determined. The related impurities were determined by spotting higher concentration of the drugs so as to detect and quantify them. Recovery studies of drugs were carried out for accuracy parameters. These studies were carried out at three levels, i.e., multiple level recovery studies. Sample stock solution
Limit of detection (ng/spot) Specific Specific from tablet formulation of 1 mg/ml and 100 µg/ml of Limit of quantification (ng/spot) atorvastatin and ezetimibe respectively was prepared. To A summary of validation parameters of atorvastatin calcium and ezetimibe the above prepared solution, 50%, 100%, 150% of the standard atorvastatin solution and 20%, 40% and 60% of the The intra-day and inter-day precision (RSD) values were standard ezetimibe solution were added. Dilutions were determined for standard atorvastatin calcium (0.8-4.0 µg/ made and recovery studies were performed. Percentage spot) and ezetimibe (0.1-1.0 µg/spot) six times on the same recovery was found to be within limits, as listed in Table 2 . day and over a period of 1 w. The intra-day and interFor the detection of the related impurities, atorvastatin calcium day coefficients of variation are given in Table 1. and ezetimibe (0.1 g each) were dissolved separately in 10 ml of methanol, and these solutions were termed as sample Repeatability of sample application was assessed by solutions (10 mg/ml). One millilitre of each sample solution spotting 2 µl of atorvastatin calcium and 5 µl of ezetimibe was diluted to 10 ml with methanol, and these solutions were solution six times on a TLC plate, followed by termed as standard solutions (1000 µg/ml). Aliquots of both development of plate and recording the peak area for 6 the standard solutions (2 µl) and sample solutions (20 µl) spots. The % RSD for peak area values of atorvastatin were spotted on the plate and chromatography performed as calcium and ezetimibe was found to be 1.09 and 1.17 described earlier. The spot other than the principal spot and the spot of the starting point from the sample solution were not intense than the spot from the standard solution. The Repeatability of measurement of peak area was sample solution of atorvastatin calcium showed three determined by spotting 2 µl of atorvastatin calcium and 5 unknown additional spots at R f of 0.06, 0.41 and 0.47. The µl of ezetimibe solution on a TLC plate and developing sample solution of ezetimibe showed three unknown the plate. The separated spot was scanned five times additional spots at R f of 0.37, 0.70 and 0.76. However, the without changing the position of the plate and % RSD areas of these spots were found to be less than 0.04% as for measurement of peak area of atorvastatin and compared to the areas of standard solution spots. ezetimibe was found to be 0.143 and 0.072 respectively. To confirm the specificity of the proposed method, the The assay value for the marketed formulation was found Specificity respectively.
solution of the formulation was spotted on the TLC plate, to be within the limits, as listed in Table 3 . The low RSD developed and scanned. It was observed that the value indicated the suitability of the method for routine excipients present in the formulation did not interfere with analysis of atorvastatin and ezetimibe in pharmaceutical the peaks of atorvastatin calcium and ezetimibe. dosage forms. www.ijpsonline.com
The developed HPTLC technique is simple, precise, specific and accurate, and the statistical analysis proved that method is reproducible and selective for the analysis of atorvastatin and ezetimibe simultaneously in bulk drug and tablet formulations.
